SCHEMBL9892932

SCHEMBL9892932

O=C(Nc1nsc(-c2ccccc2)n1)[C@@H]1CCN1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
TP53 P04637 2/20 0.53
HSD17B10 Q99714 2/20 0.53
HTT P42858 5/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
GAA P10253 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 3/20 0.52
MAPT P10636 2/20 0.52
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
NPY5R Q15761 1/20 0.43
RECQL P46063 1/20 0.43
ADORA1 P30542 6/20 0.42
ADORA3 P0DMS8 5/20 0.42
ADORA2A P29274 4/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16253075 0.93 KDM4E (0.49) KDM4ETP53HSD17B10HTTNPC1
SCHEMBL13257156 0.93 KDM4E (0.49) KDM4ETP53HSD17B10HTTNPC1
SCHEMBL9892835 0.78 ADORA3 (0.67) TP53HSD17B10HTTNPC1RAB9A
SCHEMBL7656935 0.75 KDM4E (0.63) KDM4ETP53HSD17B10HTTNPC1
SCHEMBL13842699 0.75 KDM4E (0.63) KDM4ETP53HSD17B10HTTNPC1
SCHEMBL20458152 0.74 KDM4E (0.41) KDM4ETP53HSD17B10HTTNPC1
SCHEMBL9892895 0.73 LMNA (0.63) KDM4ETP53HSD17B10HTTNPC1
SCHEMBL13257010 0.72 ADORA3 (0.68) TP53HSD17B10HTTNPC1RAB9A
SCHEMBL13257168 0.72 ADORA3 (0.68) TP53HSD17B10HTTNPC1RAB9A
SCHEMBL9891546 0.72 CNR2 (0.47) KDM4ETP53HSD17B10HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 KDM4E 1578/4885TP53 4827/4885HSD17B10 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.